Prostatic Neoplasms, Castration-Resistant Clinical Trial
— INSPIREOfficial title:
Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab for Molecular- Selected Patients With Castration-resistant Prostate Cancer
Verified date | April 2024 |
Source | Radboud University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the effects of 4 cycles of combinatory immunotherapy (ipilimumab and nivolumab), followed by monotherapy nivolumab in participants with immunogenic metastatic castration-resistant prostate cancer.
Status | Active, not recruiting |
Enrollment | 69 |
Est. completion date | February 15, 2026 |
Est. primary completion date | August 15, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Written informed consent. 2. Histological diagnosis of adenocarcinoma of the prostate. Patients who have no histological diagnosis must be willing to undergo a biopsy to prove prostate adenocarcinoma. 3. Metastatic Castration-Resistant Prostate Cancer (mCRPC), metastatic disease defined either as measurable disease by RECIST1.1 criteria or presence of bone-metastatic disease evaluable per PCWG3 criteria. For cohort 1, measurable disease is compulsory. 4. An immunogenic phenotype, consisting of one of the next criteria: 1, mismatch repair deficiency and/or a high mutational burden of >7 mutations per Mb (cluster A); 2, BRCA2 inactivation or BRCAness signature (cluster B); 3, a tandem duplication signature and/or CDK12 biallelic inactivation (cluster C) 5. Age =18 years. 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. 7. PSA = 2 ng/ml. 8. Documented willingness to use an effective means of contraception while participating in the study and for 7 months post last dose of treatment 9. Documented ongoing castrate serum testosterone <50 ng/dL (<2.0 nM). 10. Received prior castration by orchiectomy and/or ongoing Luteinizing Hormone-Releasing Hormone (LH-RH) agonist treatment. 11. Progression of disease by: 1. PSA utilizing PCWG3 criteria 2. Bone scan: disease progression as defined by at least 2 new lesions on bone scan. 3. Soft tissue disease progression defined by modified RECIST 1.1. 4. Clinical progression with worsening pain and the need for palliative radiotherapy for bone metastases. 12. Having a biopsiable metastatic lesion and willingness to undergo a baseline* and on treatment tumour biopsy for next-generation sequencing and biomarker analyses. - When sufficient FFPE material is available from a biopsy in castrate-state, one may apply for a waiver for a new baseline biopsy. Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: 1. Prior treatment with checkpoint immunotherapy (CTLA-4, or PD-1 and PD-L1 antagonists) for cohort 1. For cohort 2, patients may have prior treatment with monotherapy CTLA-4 or PD-1 or PD-L1. 2. Surgery or chemotherapy within 4 weeks prior to trial entry / randomisation into the study. Any other therapies for prostate cancer, other than GnRH analogue therapy and osteoporosis preventing agents, are not allowed. 3. Radiotherapy within 2 weeks prior to trial entry. Radiation-related side effects higher than grade 1, or above baseline. 4. Participation in another interventional clinical trial and any concurrent treatment with any investigational drug within 4 weeks prior to trial entry/randomisation. 5. History of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumours, brain metastases, or alcoholism. 6. Untreated or symptomatic brain or leptomeningeal involvement. 7. Inadequate organ and bone marrow function as evidenced by: 1. hemoglobin <6.2 mmol/L 2. Absolute neutrophil count <1.0 x 109/L 3. Platelet count < 75 x 109/L 4. Albumin <30 g/dL. 5. AST / SGOT and/or ALT / SGPT = 2.5 x ULN (= 5 x ULN if liver metastases present) 6. Total bilirubin = 1.5 x ULN (except for patient with documented Gilbert's disease) 7. Serum Creatinine > 1.5 x ULN 8. Any of the following cardiac criteria; a. Any clinically significant abnormalities in rhythm conduction, or morphology of a resting ECG (e.g., complete left bundle branch block, third degree heart block) c. Experience of any of the following procedures or conditions in the preceding six months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, congestive heart failure NYHA = Grade2 d. Uncontrolled hypotension defined as systolic blood pressure (BP) <90mmHg and/or diastolic BP <50mmHg 9. Clinically significant history of liver disease consistent with Child-Pugh Class B or C, including viral or other hepatitis, current alcohol abuse, or cirrhosis. 10. History of clinically relevant auto-immune disease (including Crohn's disease or ulcerative colitis). Any other finding giving reasonable suspicion of a disease or condition that contraindicates the use of nivolumab or ipilimumab or that may affect the interpretation of the results or renders the patients at high risk from treatment complications. 11. Need for chronic corticosteroid therapy of >10 mg of prednisolone or >0.5mg of dexamethasone per day or an equivalent dose of other anti-inflammatory corticosteroid. Patients in which corticosteroids cannot be stopped prior to entering the trial are allowed a maximum of 10mg of prednisolone per day or equivalent. In the case of corticosteroid discontinuation, a 2-week (14 days) washout is required with a mandatory PSA check prior to starting the trial. If the PSA has declined compared to the value obtained prior to stopping corticosteroids, patients will not be eligible for study. Patients can only enter the study with a confirmed PSA increase. 12. Malignancies other than prostate cancer within 3 years prior to trial entry / randomization, except for adequately treated basal or squamous cell skin cancer and non-muscle invasive bladder cancer. 13. Active second malignancy, except basal or squamous cell skin cancer and non-muscle invasive bladder cancer. Other treated malignancies with curative intent, including colorectal cancer, may be included following PI consent. 14. Unresolved clinically significant toxicity from prior therapy except for alopecia and Grade 1 peripheral neuropathy. 15. Inability to comply with study and follow-up procedures. 16. Patients with predominant small cell or neuroendocrine prostate cancer are not eligible. 17. Patients without measurable lesion per RECIST1.1, and with a superscan on bone scintigraphy not evaluable per PCWG3 criteria, are not eligible |
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboudumc | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center | Bristol-Myers Squibb |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Translational endpoint: biomarkers | To further optimize and validate predictive and early response immunogenic signatures from biomarkers in tissue and blood, associating with an objective response and disease control (DCR) of at least 6 months. | Through study completion, an average of 2 years | |
Primary | Efficacy endpoint: DCR | For patients with RECIST1.1 evaluable disease this includes a change from baseline in tumour volume as measured by PR or CR by best ORR, or an SD, all lasting longer than 6mo, and the absence of clinical disease progression.
In patients without RECIST1.1 evaluable disease, disease control is defined by the absence of new measurable lesions and unequivocal PD of non-target lesions on CT scan, the absence of bone progression as defined by the PCWG3 criteria, and the absence of clinical disease progression |
At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49 | |
Secondary | Safety endpoint: adverse effects | Percentage of Grade 3/4 and 5 treatment-related adverse effects | At inclusion, Weeks 1, 4, 7, 10, 13, 17, 21, 25, 29, 33, 37, 41, 45, and 49, and at end of treatment (typically at one year, or earlier when treatment is stopped prematurely) | |
Secondary | Efficacy endpoint: ORR | Best objective response rate (ORR) per RECIST1.1 criteria (cohort A1 only) | At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49 | |
Secondary | Efficacy endpoint: BRR | Biochemical response rate (BRR) at week 13 and maximal PSA decline according to PCWG3 criteria | BRR at Week 13, PSA at inclusion, Weeks 1, 4, 7, 10, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 and at end of treatment (typically one year, or earlier when treatment is stopped prematurely) | |
Secondary | Efficacy endpoint: rPFS | Radiographic progression free survival per irRECIST1.1 immune-related response criteria | At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49 | |
Secondary | Efficacy endpoint: OS | Overall survival | Follow-up of 1 year following trial discontinuation (onwards from the 30-day safety follow-up visit). | |
Secondary | Efficacy in the BRCA, CDK12 and MSI/hTMB subgroups | DCR, ORR, BRR, rPFS and OS per subgroup | At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49 | |
Secondary | Efficacy in the subgroup of patients with prior RT | DCR, ORR, BRR, rPFS and OS in patients with and without prior radiotherapy | At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03325127 -
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
|
||
Withdrawn |
NCT02906605 -
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05743621 -
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT02204072 -
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
|
Phase 1 | |
Recruiting |
NCT05393791 -
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
|
Phase 2 | |
Completed |
NCT03927391 -
Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects
|
Phase 4 | |
Completed |
NCT02450812 -
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
|
||
Recruiting |
NCT06353386 -
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03431350 -
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03822845 -
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02162836 -
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT02899104 -
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
|
||
Active, not recruiting |
NCT04381832 -
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03563014 -
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
|
||
Active, not recruiting |
NCT05968599 -
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
|
||
Active, not recruiting |
NCT02803437 -
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
|
||
Recruiting |
NCT05944237 -
HTL0039732 in Participants With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03173859 -
Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
|
Phase 2 | |
Terminated |
NCT02057666 -
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 3 |